What Unicycive Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Aggarwal Gaurav | Director | Aug 25 | Derivative Conversion · C | +652,900 | — | — | 1,789,915 |
| Aggarwal Gaurav | Director | Feb 18 | Derivative Conversion · C | +1,400,000 | — | — | 11,370,152 |
| Aggarwal Gaurav | Director | Oct 09 | Derivative Conversion · C | +5,500,000 | — | — | 9,970,152 |
| Gupta Shalabh K. | CEO | Jul 11 | Exercise / conversion · M | +104,612 | — | — | 2,527,449 |
| Gupta Pramod | EVP, Pharmaceuticals and BD | Jul 11 | Exercise / conversion · M | +41,845 | — | — | 41,845 |
| Jermasek Douglas | EVP of Corporate Strategy | Jul 11 | Exercise / conversion · M | +104,612 | — | — | 175,012 |
| Aggarwal Gaurav | Director | Jul 11 | Derivative Conversion · C | +3,470,152 | — | — | 3,470,152 |
| Schiller Brigitte | Director | May 16 | Open-market buy · P | +15,000 | $0.83 | +$12.4K | 15,000 |
Loading...
